other material
confidence high
sentiment positive
materiality 0.75
BioAge reports positive Phase 1 interim data for NLRP3 inhibitor BGE-102; 90-98% IL-1β suppression
BioAge Labs, Inc.
- BGE-102 well-tolerated across all doses (SAD: 10-120 mg; MAD: 60-120 mg); AEs mild/moderate, all resolved.
- 90-98% suppression of IL-1β at Day 14; doses ≥60 mg exceeded IC90 in CSF, demonstrating high brain penetration.
- Phase 1 expanded to MAD cohorts in obese participants with elevated hsCRP; data expected 1H26.
- Phase 2a proof-of-concept planned for 1H26 (100 patients, 12 weeks, primary endpoint % hsCRP change); data readout 2H26.
- Pharmacokinetics support once-daily oral dosing; dose proportionality observed.